High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited. METHODS: In this multicenter study, the Medical Research Council Myeloma VII Trial, we randomly assigned 407 patients with previously untreated multiple myeloma who were younger than 65 years of age to receive either standard conventional-dose combination chemotherapy or high-dose therapy and an autologous stem-cell transplant. RESULTS: Among the 401 patients who could be evaluated, the rates of complete response were higher in the intensive-therapy group than in the standard-therapy group (44 percent vs. 8 percent, P<0.001). The rates of partial response were similar (42 percent and 40 percent, respectively; P=0.72), and the rates of minimal response were lower in the intensive-therapy group than in the standard-therapy group (3 percent vs. 18 percent, P<0.001). Intention-to-treat analysis showed a higher rate of overall survival (P=0.04 by the log-rank test) and progression-free survival (P<0.001) in the intensive-therapy group than in the standard-therapy group. As compared with standard therapy, intensive treatment increased median survival by almost 1 year (54.1 months [95 percent confidence interval, 44.9 to 65.2] vs. 42.3 months [95 percent confidence interval, 33.1 to 51.6]). There was a trend toward a greater survival benefit in the group of patients with a poor prognosis, as defined by a high beta2-microglobulin level (more than 8 mg per liter). CONCLUSIONS: High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ASCT improves median OS in multiple myeloma by approximately 12 months.125–128”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [126]
Citations
Cites
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., et al. (1997) · Blood · doi:10.1182/blood.v89.3.789 · Cited by 541
HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
MCELWAIN, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 510
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55.401k04_55_65 · Cited by 502
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laı̈, J.-L., Leleu, X., Jouet, J.-P., Bauters, F., et al. (2001) · Blood · doi:10.1182/blood.v97.6.1566 · Cited by 312
Lenhoff, S., Hjorth, M., Holmberg, E. C., Turesson, I., Westin, J., Nielsen, J. L., Wislöff, F., Brinch, L., Carlson, K. E., Carlsson, M. S., et al. (2000) · PubMed · doi:10.1182/blood.v95.1.7 · Cited by 310
Research works printed but not linked: 7
- Morgan G, Selby P. Myeloma. In: Souhami R, Tannock I, Hohenberger P, Horiot J-C, eds. Oxford textbook of oncology. 2nd ed. Vol. 2. Oxford, England: Oxford University Press, 2001:2419-55.
- Lenhoff S, 2000, Blood, 95, 7
- Fermand J-P, 1999, Blood, 94, 396a
- Review manager (RevMan), version 4.1. Oxford, England: Cochrane Collaboration, 2000.
- Blade J, 2001, Blood, 98, 815a
- Segeren CM, 2001, Blood, 98, 815a
- Fermand J-P, 2001, Blood, 98, 815a
Cited by
Items 301–400 of 1,000
Chang, H., Qi, X. Y., Samiee, S., Yi, Q., Chen, C., Trudel, S., Mikhael, J. R., Reece, D. E., & Stewart, A. K. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705131 · Cited by 67
Protein Transduction of Dendritic Cells for NY-ESO-1-Based Immunotherapy of Myeloma
Batchu, R. B., Moreno, A., Szmania, S. M., Bennett, G., Spagnoli, G. C., Ponnazhagan, S., Barlogie, B., Tricot, G. J. K., & van Rhee, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1383 · Cited by 69
“Autologous blood stem cell–supported high-dose melphalan therapy has emerged as the treatment of choice for the primary care of younger patients with multiple myeloma (1, 2).”
BackgroundAutologous stem cell transplant for multiple myeloma patients 70 years or older
Muchtar, E., Dingli, D., Kumar, S. K., Buadi, F. K., Dispenzieri, A. A., Hayman, S. R., Wolf, R. C., Gastineau, D. A., Chakraborty, R., Hogan, W. J., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.174 · Cited by 71
Kim, H., Sohn, H.-J., Kim, S. M., Lee, J. S., Kim, W., & Suh, C. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705373 · Cited by 66
Cavallo, F., Bringhen, S., Milone, G., Ben‐Yehuda, D., Nagler, A., Calabrese, E., Cascavilla, N., Montefusco, V., Lupo, B., Liberati, A. M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.131 · Cited by 67
Multiple myeloma – an update on diagnosis and treatment
Caers, J., Broek, I. V., Raeve, H. D., Michaux, L., Trullemans, F., Schots, R., Camp, B. V., & Vanderkerken, K. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01127.x · Cited by 75
In and out of the niche: perspectives in mobilization of hematopoietic stem cells
Mohty, M., & Ho, A. D. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.05.004 · Cited by 74
Cook, G., Liakopoulou, E., Pearce, R., Cavet, J., Morgan, G. J., Kirkland, K., Lee, J., Davies, F. E., Hall, R., Rahemtulla, A., et al. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.04.005 · Cited by 67
“For younger patients withMM, the standard of care is induction therapy consolidated with high-dose melphalan (HDM) and autologous peripheral blood stem cell (ASCT) rescue [2-4].”
BackgroundSelf-citationRay, A., Ravillah, D., Das, D. S., Song, Y. Y., Nordström, E. K. L., Gullbo, J., Richardson, P. G. G., Chauhan, D., & Anderson, K. C. (2016) · British Journal of Haematology · doi:10.1111/bjh.14065 · Cited by 63
“High-dose melphalan together with autologous stem cell transplantation increased progression-free and overall survival in transplant candidates (Attal et al, 1996; Child et al, 2003; Barlogie et al, 2006; Falco et al, 2013).”
BackgroundGoldschmidt, H., Baertsch, M., Schlenzka, J., Becker, N., Habermehl, C., Hielscher, T., Raab, M., Hillengaß, J., Sauer, S., Müller‐Tidow, C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0948-0 · Cited by 70
“Initial randomized trials demonstrated superiority over conventional dose chemotherapy in terms of both PFS and overall survival (OS) [3, 4].”
BackgroundStewart, A. K., Chen, C. I., Howson‐Jan, K., White, D. J., Roy, J., Kovacs, M. J., Shustik, C., Sadura, A., Shepherd, L. E., Ding, K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1106 · Cited by 67
The emerging role of exosomes in multiple myeloma
Moloudizargari, M., Abdollahi, M. R., Asghari, M. H., Zimța, A., Berindan‐Neagoe, I., & Nabavi, S. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100595 · Cited by 63
Prolonged overall survival with second on-demand autologous transplant in multiple myeloma
Elice, F., Raimondi, R., Tosetto, A., D’Emilio, A., Bona, E. D., Piccin, A., & Rodeghiero, F. (2006) · American Journal of Hematology · doi:10.1002/ajh.20641 · Cited by 63
Antibody-maytansinoid conjugates for the treatment of myeloma
Lutz, R. J., & Whiteman, K. R. (2009) · mAbs · doi:10.4161/mabs.1.6.10029 · Cited by 64
Ogawa, Y., Tobinai, K., Ogura, M., Ando, K., Tsuchiya, T., Kobayashi, Y., Watanabe, T., Maruyama, D., Morishima, Y., Kagami, Y., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00638.x · Cited by 64
Flow Cytometric Immunophenotyping and Minimal Residual Disease Analysis in Multiple Myeloma
Gupta, R., Bhaskar, A., Kumar, L., Sharma, A., & Jain, P. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcp1gyi7ehqyuyk · Cited by 71
Wildes, T. M., Stirewalt, D. L., Medeiros, B. C., & Hurria, A. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0010 · Cited by 64
Hogan, J. J., & Weiss, B. M. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03160316 · Cited by 68
Green, D. J., O’Steen, S., Lin, Y., Comstock, M., Kenoyer, A. L., Hamlin, D. K., Wilbur, D. S., Fisher, D. R., Nartea, M. E., Hylarides, M. D., et al. (2017) · Blood · doi:10.1182/blood-2017-09-807610 · Cited by 66
Langseth, Ø. O., Myklebust, T. Å., Johannesen, T. B., Hjertner, Ø., & Waage, A. (2020) · British Journal of Haematology · doi:10.1111/bjh.16674 · Cited by 63
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Harousseau, J., & Dreyling, M. H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq178 · Cited by 76
Bird, J. M., Fuge, R., Sirohi, B., Apperley, J. F., Hunter, A., Snowden, J. A., Mahendra, P., Milligan, D. W., Byrne, J., Littlewood, T. J., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06191.x · Cited by 64
“Several large national randomised studies provided strong evidence for the role of HDT and autologous SCT in the management of patients with myeloma, making it a standard of care (Attal et al, 1996; Child et al, 2003).”
BackgroundMethodKyle, R. A., Leong, T., Li, S., Oken, M. M., Kay, N. E., Van Ness, B., & Greipp, P. R. (2006) · Cancer · doi:10.1002/cncr.21804 · Cited by 62
Micallef, I. N. M., Ho, A. D., Klein, L. M., Marulkar, S., Gandhi, P. J., & McSweeney, P. A. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.118 · Cited by 61
Sive, J. I., Cuthill, K., Hunter, H. M., Kazmi, M. A., Pratt, G., Smith, D., & British Society of Haematology (2021) · British Journal of Haematology · doi:10.1111/bjh.17410 · Cited by 69
Zhang, S., Suvannasankha, A., Crean, C., White, V. L., Johnson, A. J., Chen, C., & Farag, S. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0136 · Cited by 62
“sion-free survival and overall survival, but almost all patients relapse following transplantation (2, 3).”
BackgroundVogl, D. T., Wang, T., Pérez, W. S., Stadtmauer, E. A., Heitjan, D. F., Lazarus, H. M., Kyle, R. A., Kamble, R., Weisdorf, D. J., Roy, V., et al. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.05.005 · Cited by 65
“Novel antimyeloma agents have improved outcomes for patients, but the first major advance in myeloma therapy since the 1960s was the demonstration that autologous hematopoietic stem cell transplantation (AutoHCT) improves survival [1,2].”
BackgroundSomlo, G., Spielberger, R. T., Frankel, P. H., Karanes, C., Krishnan, A. Y., Parker, P. M., Popplewell, L. L., Sahebi, F., Kogut, N. M., Snyder, D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1912 · Cited by 64
“Single and tandem autologous stem cell transplantation (TASCT) have improved CR and VGPR rates, leading to improved progressionfree (PFS) and overall survival (OS) (4-6).”
BackgroundGambell, P. C., Herbert, K. E., Dickinson, M. J., Stokes, K. H., Bressel, M., Wall, D. M., Harrison, S. J., & Prince, H. M. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.10.002 · Cited by 61
“High-dose chemotherapy and autologous hematopoietic progenitor cell (HPC) transplantation is established therapy for various hematologic cancers and solid tumors [1-6].”
Backgroundvan der Poel, M., Oerlemans, S., Schouten, H. C., & van de Poll-Franse, L. V. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2264-0 · Cited by 64
Nadal, E., Giné, E., Bladé, J., Esteve, J., Rosiñol, L., Fernández‐Avilés, F., Marín, P., Martínez, C., Rovira, M., Urbano-Ispizúa, Á., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704313 · Cited by 62
Bone marrow transplantation generates T cell–dependent control of myeloma in mice
Vučković, S., Minnie, S. A., Smith, D. D., Gartlan, K. H., Watkins, T. S., Markey, K. A., Mukhopadhyay, P., Guillerey, C., Kuns, R. D., Locke, K. R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98888 · Cited by 63
“Indeed, stem cell transplantation (SCT) remains a standard of care for MM patients of appropriate age and performance status (4, 5).”
BackgroundEpidemiology, genetics and treatment of multiple myeloma and precursor diseases
Hemminki, K., Försti, A., Houlston, R. S., & Sud, A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33762 · Cited by 70
Role of autologous and allogeneic stem cell transplantation in myeloma
Bensinger, W. (2009) · Leukemia · doi:10.1038/leu.2008.396 · Cited by 65
“Galimberti 64 20 (0) TBI 2Gy,Flu (10) Cy, Flu (10) 20 CSA Mmf 25 30 20 35 58 (2)”
Orsini, F., Rotschild, C., Beurrier, P., Faradji, A., Goudemand, J., & Polack, B. (2005) · PubMed · Cited by 65
Sellner, L., Heiß, C., Benner, A., Raab, M. S., Hillengaß, J., Hose, D., Lehners, N., Egerer, G., Ho, A. D., Goldschmidt, H., et al. (2013) · Cancer · doi:10.1002/cncr.28104 · Cited by 61
Tuchman, S. A., Bacon, W., Huang, L., Long, G. D., Rizzieri, D. A., Horwitz, M. E., Chute, J. P., Sullivan, K. M., Engemann, A. M., Yopp, A., et al. (2014) · Journal of Clinical Apheresis · doi:10.1002/jca.21360 · Cited by 65
“ASCT remains a standard of care for MM, prolonging remission and in some studies OS as compared with conventional chemotherapy [1,23–25].”
Maiolino, Â., Hungria, V., Garnica, M., Oliveira-Duarte, G. B., de Oliveira, L. C. O., Mercante, D., MIRANDA, E. C. M., Quero, A. A., Peres, A. L., Barros, J. C., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23274 · Cited by 64
“Compared with conventional chemotherapy, ASCT has been shown to improve response rates and prolong progression-free survival (PFS), and overall survival (OS) [1,2].”
BackgroundEmerging therapies for multiple myeloma
Podar, K., Tai, Y., Hideshima, T., Vallet, S., Richardson, P. G. G., & Anderson, K. C. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802676278 · Cited by 62
“Of note, autologous SCT followed by allografting with nonmyeloablative conditioning achieved dramatic reduction of transplant-related mortality with potent antitumor activity [50,51] .”
BackgroundInfluentialEfficacy and outcome of autologous transplantation in rare myelomas
Morris, C., Drake, M. B., Apperley, J. F., Iacobelli, S., van Biezen, A., Björkstrand, B., Goldschmidt, H., Harousseau, J., Morgan, G. J., de Witte, T., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.022848 · Cited by 60
Self-citation166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
Breitz, H. B., Wendt, R. E., Stabin, M., Shen, S., Erwin, W. D., Rajendran, J. G., Eary, J. F., Durack, L. D., Delpassand, E. S., Martin, W., et al. (2006) · PubMed · Cited by 59
How to Treat High-Risk Myeloma at Diagnosis and Relapse
Caro, J., Hadidi, S. A., Usmani, S. Z., Yee, A. J., Raje, N. S., & Davies, F. E. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320105 · Cited by 58
Self-citationYasui, H., Hideshima, T., Hamasaki, M., Roccaro, A. M., Shiraishi, N., Kumar, S. K., Tassone, P., Ishitsuka, K., Raje, N. S., Tai, Y., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0838 · Cited by 63
Jantunen, E., Itälä, M., Lehtinen, T., Kuittinen, O. M., Koivunen, E., Leppä, S., Juvonen, E., Koistinen, P., Wiklund, T. A., Nousiainen, T., et al. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00605.x · Cited by 58
“of the patients receiving HD-MEL died <100 d from ASCT (21).”
BackgroundWeißinger, F., Auner, H. W., Bertz, H., Buchheidt, D., Cornely, O. A., Egerer, G., Heinz, W., Karthaus, M., Kiehl, M. G., Krüger, W., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1456-8 · Cited by 61
Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma
Kumar, S. K., Lacy, M. Q., Dispenzieri, A. A., Rajkumar, S. V., Fonseca, R., Geyer, S. M., Allmer, C., Witzig, T. E., Lust, J. A., Greipp, P. R., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704633 · Cited by 59
Lefrère, F., Brignier, A. C., Elie, C., Ribeil, J., Bernimoulin, M. P., Aoun, C., Cortivo, L. D., Delarue, R., Hermine, O., & Cavazzana, M. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0009-1 · Cited by 57
Landau, H. J., McNeely, S., Nair, J. S., Comenzo, R. L., Asai, T., Friedman, H., Jhanwar, S. C., Nimer, S. D., & Schwartz, G. K. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0949 · Cited by 64
“While traditional chemotherapy regimens including alkylating agents and anthracyclines have modest benefits in this disease, high dose melphalan supported by autologous stem cell transplantation has been shown to increase the incidence of complete and near complete remissions to ~50% of patients.(1) However, almost al…”
BackgroundNath, C. E., Trotman, J., Tiley, C., Presgrave, P., Joshua, D., Kerridge, I., Kwan, Y. L., Gurney, H., McLachlan, A. J., Earl, J. W., et al. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12906 · Cited by 59
Carlson, K. E. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704948 · Cited by 59
Afifi, S., Adel, N., Devlin, S. M., Duck, E., Vanak, J. M., Landau, H. J., Chung, D. J., Lendvai, N. K., Lesokhin, A. M., Korde, N., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.322 · Cited by 60
Harding, T., Baughn, L. B., Kumar, S. K., & Ness, B. V. (2019) · Leukemia · doi:10.1038/s41375-018-0362-z · Cited by 56
Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma
Neelapu, S. S., Munshi, N. C., Jagannath, S., Watson, T. M., Pennington, R. M., Reynolds, C. G., Barlogie, B., & Kwak, L. W. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705057 · Cited by 57
Treatment for patients with newly diagnosed multiple myeloma in 2015
Mateos, M., Ocio, E. M., Paiva, B., Rosiñol, L., Martínez‐López, J., Bladé, J., Lahuerta, J. J., García‐Sánz, R., & Miguel, J. F. S. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.06.001 · Cited by 61
“Before the introduction of novel agents, ASCT was considered the standard approach for young patients with newly diagnosed MM, although only two [63,64] of five [63–67] randomised clinical trials (Table 3) comparing conventional chemotherapy and ASCT showed a survival advantage.”
Schey, S. A., Morgan, G. J., Ramasamy, K., Hazel, B., Ladon, D., Corderoy, S., Jenner, M., Phekoo, K., Boyd, K., & Davies, F. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08250.x · Cited by 57
“…equivalent efficiency of cyclophosphamide to melphalan and highlighted its favourable toxicity profile, with less profound myelosuppression (Augustson et al, 2005) and lacking the stem cell toxicity of melphalan, making it safe to use in patients destined for transplantation (Child et al, 2003).”
BackgroundSelf-citationTeh, B. W., Harrison, S. J., Pellegrini, M., Thursky, K., Worth, L. J., & Slavin, M. A. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.01.004 · Cited by 61
“AutoHCT provides effective haematopoietic support, allowing the delivery of HDT and is associated with improved disease response [91,92].”
BackgroundStem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
Bensinger, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6863 · Cited by 61
Tosi, P., Zamagni, E., Cellini, C., Parente, R., Cangini, D., Tacchetti, P., Perrone, G., Ceccolini, M., Boni, P., Tura, S., et al. (2006) · European Journal Of Haematology · doi:10.1111/j.0902-4441.2005.t01-1-ejh2520.x · Cited by 56
“conventional chemotherapy in terms of response and survival (3, 4).”
BackgroundGerull, S., Göerner, M., Benner, A., Hegenbart, U., Klein, U., Schaefer, H., Goldschmidt, H., & Ho, A. D. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705161 · Cited by 58
de la Rubia, J., Bladé, J., Lahuerta, J.-J., Ribera, J., Martínez, R., Alegre, A. M., García‐Laraña, J., Fernández, P., Sureda, A. M., de Arriba, F., et al. (2006) · PubMed · Cited by 61
Alici, E., Konstantinidis, K. V., Sütlü, T., Aints, A., Gahrton, G., Ljunggren, H., & Dilber, M. S. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.08.006 · Cited by 55
Increased fatty acid synthase as a potential therapeutic target in multiple myeloma
Wang, W., Zhao, X., Wang, H., & Liang, Y. (2008) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b0740640 · Cited by 54
“The current standard treatment with high-dose chemotherapy followed by autologous stem cell transplant prolongs survival to a median of 4~5 years compared to 3 years in conventional chemotherapy (Child et al., 2002).”
BackgroundNew agents in HSC mobilization
Domingues, M. J., Nilsson, S. K., & Cao, B. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2156-2 · Cited by 60
Labonté, L. E., Iqbal, T. H., Zaidi, M. A., McDiarmid, S. A., Huebsch, L. B., Tay, J., Atkins, H. L., & Allan, D. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.06.019 · Cited by 56
Zver, S., Zadnik, V., Bunc, M., Rogel, P., Černelč, P., & Koželj, M. (2007) · International Journal of Hematology · doi:10.1532/ijh97.e0620 · Cited by 58
“High-dose (HD) myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) has been associated with higher response rates and better survival in patients with multiple myeloma than conventional treatments [1,2].”
BackgroundSafety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma
Graff, T. M., Singavi, A. K., Schmidt, W., Eastwood, D. C., Drobyski, W. R., Horowitz, M. M., Palmer, J. M., Pasquini, M. C., Rizzo, D., Saber, W., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.46 · Cited by 57
Al‐Farsi, K. (2013) · Oman Medical Journal · doi:10.5001/omj.2013.02 · Cited by 61
Melphalan hydrochloride for the treatment of multiple myeloma
Esma, F., Salvini, M., Troia, R., Boccadoro, M., Larocca, A., & Pautasso, C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1349102 · Cited by 58
“Pivotal trial(s) Alexanian et al [20]; San Miguel et al [21]; Fayers et al [22]; Attal et al [23]; Child et al [24]; Palumbo et al [25]”
BackgroundInfluentialVerelst, S. G. R., Blommestein, H. M., de Groot, S., Gonzalez‐McQuire, S., DeCosta, L., de Raad, J. B., Groot, C. A. U., & Sonneveld, P. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000045 · Cited by 57
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A. A., Cohen, A. D., Devine, S. M., Djulbegović, B., Faber, E. A., Gasparetto, C., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0095 · Cited by 68
van Agthoven, M., Segeren, C. M., Buijt, I., Groot, C. A. U., van der Holt, B., Lokhorst, H. M., & Sonneveld, P. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.019 · Cited by 59
“After all, despite the high costs, myeloablative treatment appears to result in improved outcome measures after a longer follow-up duration, and may finally result in a significant higher overall survival, as was shown before [9,10].”
BackgroundArora, M., Burns, L. J., Barker, J. N., Miller, J. S., DeFor, T. E., Olujohungbe, A., & Weisdorf, D. J. (2004) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2004.02.001 · Cited by 56
Costa, L. J., Abbas, J. A., Hogan, K. R., Kramer, C., McDonald, K., Butcher, C., Littleton, A., Shoptaw, K. B., Kang, Y., & Stuart, R. K. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.60 · Cited by 55
Kühne, A., Sezer, O., Heider, U., Meineke, I., Muhlke, S., Niere, W., Overbeck, T. R., Hohloch, K., Trümper, L. H. P., Brockmöller, J., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100336 · Cited by 56
“Alternatively, high-dose melphalan followed by autologous bone marrow transplantation is applied in patients younger than 60 years of age with stage-II and -III multiple myeloma.(3,4) Several clinical studies showed that an increasing melphalan dose results in a better response,(5,6) but with increasing dose there is…”
BackgroundVogel, W., Kopp, H., Kanz, L., & Einsele, H. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0635-y · Cited by 59
“High-dose chemotherapy with autologous stem cell rescue is an effective first line treatment for patients with multiple myeloma who are younger than 65 years of age [1, 2, 4].”
BackgroundRaje, N. S., Vadhan‐Raj, S., Willenbacher, W., Terpos, E., Hungria, V., Spencer, A. G., Alexeeva, Y., Facon, T. T. F., Stewart, A. K., Feng, A. J., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2015.96 · Cited by 53
Multiple myeloma: the bone marrow microenvironment and its relation to treatment
Andrews, S. W., Kabrah, S. M., May, J. E., Donaldson, C., & Morse, H. (2013) · British Journal of Biomedical Science · doi:10.1080/09674845.2013.11669945 · Cited by 55
Yang, B., Yu, R.-L., Chi, X.-H., & Lu, X.-C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064354 · Cited by 53
“A number of therapeutic approaches and treatment combinations have been employed in the treatment of MM, relying primarily on high dose chemotherapy and autologous stem-cell transplantation [5], maintenance therapy using drug regimens such as alternate-day prednisone [6], and high-dose chemoradiotherapy [7].”
Berenson, J. R., Yellin, O., Bessudo, A., Boccia, R. V., Noga, S. J., Gravenor, D. S., Patel‐Donnelly, D., Siegel, R. S., Kewalramani, T., Gorak, E. J., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12129 · Cited by 55
“High-dose chemotherapy followed by autologous stem cell transplant (ASCT) demonstrated improved survival compared with conventional chemotherapy (Attal et al, 1996; Child et al, 2003; http://nccn.org/professionals/physician_gls/f_guidelines. asp) in some but not all trials (Bladé et al, 2005).”
BackgroundMicallef, I. N., Stiff, P. J., Nademanee, A. P., Maziarz, R. T., Horwitz, M. E., Stadtmauer, E. A., Kaufman, J. L., McCarty, J. M., Vargo, R. L., Cheverton, P., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.01.039 · Cited by 57
“In patients with relapsed or chemosensitive NHL, high-dose chemotherapy with auto-HSCT has been shown to increase disease-free survival [4], whereas in MM, a combination of high-dose chemotherapy with auto-HSCT improves progression-free survival (PFS) and overall survival (OS) [5,6].”
Pulte, E. D., Dmytrijuk, A., Nie, L., Goldberg, K. B., McKee, A. E., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0440 · Cited by 51
“For younger and fit patients with symptomatic newly diagnosed multiple myeloma (NDMM), high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care and leads to longer progression-free survival (PFS) and overall survival (OS) compared with other treatment op…”
BackgroundMelphalan and its role in the management of patients with multiple myeloma
Falco, P., Bringhen, S., Avonto, I., Gay, F., Morabito, F., Boccadoro, M., & Palumbo, A. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.7.945 · Cited by 55
Bayer, A. L., Jones, M., Chirinos, J., de Armas, L. R., Schreiber, T. H., Malek, T. R., & Levy, R. B. (2008) · Blood · doi:10.1182/blood-2008-08-173179 · Cited by 51
Kvam, A. K., Fayers, P. M., Hjermstad, M. J., Gulbrandsen, N., & Wislöff, F. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01303.x · Cited by 56
Li, S., Xue, F., Cheng, Z., Yang, X., Wang, S., Geng, F., & Pan, L. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0409-z · Cited by 52
“[1–3].”
Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing
Kumar, S. K., Buadi, F. K., & Rajkumar, S. V. (2018) · Blood · doi:10.1182/blood-2018-08-825349 · Cited by 55
Chang, H., Samiee, S., & Yi, Q. L. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500272549 · Cited by 52
Awan, F. T., Kochuparambil, S. T., Falconer, D. E., Cumpston, A., Leadmon, S., Watkins, K., DeRemer, D. L., Jillella, A., Craig, M., & Hamadani, M. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.52 · Cited by 52
Dispenzieri, A. A., Wiseman, G., Lacy, M. Q., Litzow, M. R., Anderson, P. M., Gastineau, D. A., Tefferi, A., Inwards, D. J., Micallef, I. N., Ansell, S. M., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403575 · Cited by 53
Morris, C., Iacobelli, S., Brand, R., Björkstrand, B., Drake, M. B., Niederwieser, D. W., & Gahrton, G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.144 · Cited by 51
Prognostic Factors and Staging in Multiple Myeloma
Fonseca, R., & Miguel, J. F. S. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.010 · Cited by 59
Qazilbash, M. H., Saliba, R. M., Ahmed, B., Parikh, G. C., Mendoza, F. L., Ashraf, N., Hosing, C. M., Flosser, T., Weber, D. M., Wang, M. L., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.05.014 · Cited by 57
Health related quality of life in patients with multiple myeloma undergoing a double transplantation
Groot, C. A. U., Buijt, I., Gloudemans, I. J. M., Ossenkoppele, G. J., van den Berg, H. P., & Huijgens, P. C. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00346.x · Cited by 52
“EORTC QLQ-C30 functioning scales Physical functioning 65 (28) 85 (15) 78 (19) Role functioning 53 (32) 72 (18) 71 (21) Emotional functioning 74 (19) 74 (20) 78 (19) Cognitive functioning 79 (21) 82 (21) 85 (17) Social functioning 69 (27) 82 (25) 82 (25) Global QoL 66 (23) 70 (16) 69 (19) EORTC QLQ-C30 symptoms Fatigue…”
Krejčí, M., Büchler, T., Hájek, R., Svobodník, A., Křivanová, A., Pour, L., Adam, Z., Mayer, J., & Vorlíček, J. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704728 · Cited by 51
Putkonen, M., Kairisto, V., Juvonen, V., Pelliniemi, T., Rauhala, A., Itälä‐Remes, M., & Remes, K. (2010) · European Journal of Haematology · doi:10.1111/j.1600-0609.2010.01510.x · Cited by 49
“The main finding here was that among CR and nCR patients the molecular remission rate measured with the sensitive qASO-PCR, regardless of the patient-specific assay sensitivity, was less after ASCT (53”
BackgroundInfluentialEngelhardt, M. M., Kleber, M., Udi, J., Wäsch, R., Spencer, A. G., Patriarca, F. F., Knop, S. T., Bruno, B., Gramatzki, M., Morabito, F., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.487959 · Cited by 56
CR represents an early index of potential long survival in multiple myeloma
Wang, M., Delasalle, K. B., Feng, L., Thomas, S., Giralt, S., Qazilbash, M., Handy, B. C., Lee, J. J., & Alexanian, R. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.176 · Cited by 52
Emergence of central nervous system myeloma in the era of novel agents
Gangatharan, S. A., Carney, D. A., Prince, H. M., Wolf, M. M., Januszewicz, E. H., Ritchie, D. S., & Harrison, S. J. (2011) · Hematological Oncology · doi:10.1002/hon.1021 · Cited by 50
“ASCT has been established as standard of care and widely adopted since landmark trials published in 2003 [9].”
BackgroundToor, A. A., Ayers, J., Strupeck, J., Parthasarathy, M., Creech, S., Rodriguez, T. E., & Stiff, P. J. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04837.x · Cited by 53
“…the superiority of high dose chemotherapy and autologous stem cell transplantation (ASCT) in achieving long-term disease-free survival in patients with MM when compared with patients receiving conventional therapy (Attal et al, 1996; Barlogie et al, 1997; Lenhoff et al, 2000; Child et al, 2003).”
BackgroundResultFenk, R. R., Schneider, P., Kropff, M. H., Huenerlituerkoglu, A.-N., Steidl, U. U., Aul, C., Hildebrandt, B., Haas, R. R., Heyll, A., Kobbe, G., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05641.x · Cited by 50
“Highdose chemotherapy (HDT) with autologous blood stem cell transplantation (SCT) has improved the response rates and survival of patients with MM in comparison with conventional chemotherapy (Attal et al, 1996; Child et al, 2003).”
Background
Metadata
- Authors
- Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J.
- Affiliations
- University of Leeds (GB)
- University of Birmingham (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-05-08
- Volume
- 348
- Issue
- 19
- Pages
- 1875-1883
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102591890
- Semantic Scholar
- 5d90e1ff237e9db8f41e6e1e264450eed3f77e40
- Cited by
- 1,768
- References
- 23
- Citations by year
- 2026: 17 · 2025: 26 · 2024: 34 · 2023: 36 · 2022: 41 · 2021: 57 · 2020: 83 · 2019: 46 · 2018: 71 · 2017: 76 · 2016: 73 · 2015: 71 · 2014: 81 · 2013: 103 · 2012: 94
- FWCI
- 53.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, high-dose chemotherapy, autologous stem cell transplantation, first-line therapy, complete response, overall survival, progression-free survival, beta2-microglobulin, prognostic factors, previously untreated myeloma
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Cause of Death, Combined Modality Therapy, Cyclophosphamide, Doxorubicin, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prognosis, Survival Analysis, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Alkylating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.